- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07937475
Remote Monitoring in Young Adults With Inflammatory Joint Disease (ReMonit Young)
Remote Monitoring and Personalized Patient Pathways in Young Adults With Inflammatory Joint Disease (ReMonit Young)
The goal of this clinical trial is to learn whether remote follow-up can work as well as regular in-person follow-up at the hospital for young adults with inflammatory joint diseases who have low disease activity. The study includes people aged 18 to 30 years with juvenile idiopathic arthritis, rheumatoid arthritis, psoriatic arthritis, or spondyloarthritis.
The main questions it aims to answer are:
- Is remote follow-up non-inferior (not worse than) to regular in-person follow-up at the hospital in keeping participants' disease under good control over 24 months?
- Is remote follow-up non-inferior to regular in-person follow-up when it comes to disease flare-ups, use of healthcare services, medication use, satisfaction with care, and safety? Researchers will compare a remote follow-up program, with fewer routine outpatient visits, to regular in-person follow-up to see whether disease control after 24 month is non-inferior (not worse)
Participants will:
- Be randomly assigned to either remote digital follow-up or regular in-person follow-up at the hospital .
- Complete questionnaires about their symptoms, health, and treatment during the study.
- Attend appointments with a rheumatologist at the start of the study and at study end at 24 months.
- If assigned to remote follow-up, complete questionnaires every 3 months using a smartphone or tablet application and communicate with a study nurse when needed through secure messaging in the remote monitoring software platform.
- If assigned to regular in-person follow-up, attend routine appointments at the rheumatology clinic according to usual practice.
This study aims to determine whether remote follow-up can provide a safe and effective alternative to regular in-person follow-up for young adults with inflammatory joint diseases who have low disease activity .
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This project addresses follow-up care for young adults with an inflammatory joint disease (IJD), a group facing the challenge of the transition from pediatric to adult care and with variable treatment adherence. Remote digital follow-up may support timely detection of disease worsening, self-management, and efficient use of healthcare resources. However, there is limited evidence on whether remote follow-up is non-inferior to conventional in-person follow-up at the hospital in terms of disease control, particularly in this patient group .
The main objective is to assess whether a remote, digitally supported follow-up strategy is non-inferior to conventional scheduled in-person follow-up (outpatient care) regarding maintenance of low disease activity at 24 months in young adults (18-30 years) with juvenile idiopathic arthritis, rheumatoid arthritis, spondyloarthritis, or psoriatic arthritis who are in low disease activity and at a stable dosage of disease-modifying antirheumatic drug (DMARD) treatment.
Primary endpoint: Low disease activity at 24 months, defined by diagnosis-specific composite disease activity criteria. Non-inferiority is concluded if the lower bound of the two-sided 95% confidence interval for the difference (remote minus conventional) is above -15 percentage points.
Secondary endpoints include safety (disease flares, unscheduled visits due to worsening, adverse events, medication changes), patient satisfaction, medication adherence, composite disease activity scores, and inflammatory markers. Exploratory endpoints include healthcare costs and cost-effectiveness, travel-related carbon footprint of in-person consultations, user experience, and engagement with the digital platform.
Study design: A two-arm, parallel-group, open-label, non-inferiority study where participants are randomized 1:1 to remote digital follow-up or conventional in-person follow-up, stratified by diagnosis and medication-delivery mode (hospital-administered intravenous versus self-administered treatment). The statistician performing the primary analysis will be blinded to allocation. Duration of follow-up is 24 months. All participants continue their prescribed antirheumatic treatment.
Intervention: Remote follow-up using the MyDignio digital platform. Every three months, participants answer six triage questions on symptoms, adherence, side effects, treatment interruptions, impact on daily life, and need for a consultation with a health professional. Responses indicating increased symptoms, reduced adherence, side effects, treatment interruptions, or request for contact generate an alert. A study nurse then contacts the participant and arranges a telephone or in-person consultation within two weeks if needed. Participants can also send messages, which are reviewed 2-3 times/week. Scheduled contacts are rheumatologist consultations at baseline and 24 months and a nurse consultation at 12 months.
Conventional follow-up: Standard rheumatology in-patient follow-up care with rheumatologist assessments at baseline, 12, and 24 months and consultations with a nurse at 6 and 18 months. In both arms, additional consultations are arranged when clinically indicated, using the same criteria.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Nina Østerås, PhD
- Número de telefone: +47 92086465
- E-mail: nina.osteras@diakonsyk.no
Locais de estudo
-
-
-
Oslo, Noruega, 0319
- Diakonhjemmet Hospital
-
Contato:
- NIna Østerås, PhD
- Número de telefone: +47 92086465
- E-mail: nina.osteras@diakonsyk.no
-
Contato:
- Kristine R Norden, PhD
- Número de telefone: +47 92043801
- E-mail: kristineroren.norden@diakonsyk.no
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Biological male or female aged 18-30 years at the time of informed consent
- Clinical diagnosis of JIA, RA, SpA, or PsA
- Stable DMARD treatment for ≥ 6 months; no initiation, discontinuation, or major dose escalation of a DMARD during the preceding 6 months. Temporary treatment interruptions and minor dose adjustments may be permitted.
- Inactive disease or low disease activity at inclusion, according to diagnosis specific instrument thresholds (JADAS27≤2.7, DAS28≤ 3.2, ASDAS< 2.1, DAPSA≤14)
- Ability to understand Norwegian
- Capable of providing written informed consent
- Access to a smartphone or tablet compatible with installation of the Dignio application
Exclusion Criteria:
Major co-morbidities, such as severe malignancies, severe diabetes mellitus, severe infections, uncontrollable hypertension, severe cardiovascular disease (NYHA class III or IV), severe respiratory diseases, and/or cirrhosis
- Indications of active tuberculosis (TB)
- Pregnant and/or breastfeeding
- Stills disease (systemic JIA)
- Currently enrolled in a different RCT
- Abnormal renal function, defined as serum creatinine >142 µmol/L in female and >168 µmol/L in male, or glomerular filtration rate (GFR) <40 mL/min/1.73 m2
- Abnormal liver function (defined as Alanine Transaminase (ALT) >3x upper normal limit), active or recent hepatitis
- Leukopenia and/or thrombocytopenia
- Severe psychiatric or mental disorders; current alcohol or other substance abuse; substantial language barriers; or any condition or circumstance that, in the investigator's judgment, would make adherence to the study protocol impossible.
- Planned pregnancy during the study period.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Pesquisa de serviços de saúde
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Remote digital follow-up
Structured remote follow-up for 24 months using the MyDignio digital platform, with electronic triage questionnaires every three months, nurse review of alerts and messages, and scheduled consultations at baseline, 12 and 24 months. Participants continue their prescribed antirheumatic treatment. |
Remote follow-up for 24 months using the MyDignio digital platform on the participant's smartphone or tablet, after training from the study team. Every three months, participants answer triage questions covering:
Scheduled contacts: consultations with a rheumatologist at baseline and 24 months, and a consult |
|
Comparador Ativo: Conventional hospital-based follow-up
Standard rheumatology outpatient follow-up for 24 months, with scheduled rheumatologist and nurse contacts at baseline, 6, 12, 18 and 24 months. Participants continue their prescribed antirheumatic treatment |
Convetional rheumatology outpatient follow-up for 24 months, with rheumatologist in-person assessments at baseline, 12 and 24 months and consultations with a nurse, in-person or by telephone, at 6 and 18 months. Participants may contact the study nurse between scheduled visits, and additional consultations are arranged when clinically indicated, using the same criteria as in the remote arm. Participants continue their prescribed antirheumatic treatment. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Proportion of participants in low disease activity
Prazo: Baseline and 24 months
|
Assessed using a composite score specific to diagnosis. For all scores, higher values indicate higher disease activity. Participants are considered to be in low disease activity (including remission) if they meet the following criteria: JIA: Juvenile Arthritis Disease Activity Score 27 (JADAS27) ≤ 2.7; RA: Disease Activity Score 28 joints ≤3.2; SpA: Ankylosing Spondylitis Disease Activity Score <2.1; PsA: Disease Activity in Psoriatic Arthritis (DAPSA) ≤14. |
Baseline and 24 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of participants with at least one disease flare
Prazo: 0-24 months
|
Number of participants with ≥1 disease flare. Flare is defined as: JIA: JADAS27 increase ≥1.7 from baseline and ≥1 active joint; RA: DAS28 increase ≥1.2 from baseline, or ≥0.6 if DAS28 ≥3.2; SpA: ASDAS increase ≥0.9 from baseline; PsA: DAPSA increase ≥7 from baseline; or, for all diagnoses, consensus between treating physician and participant that a clinically significant flare has occurred requiring intensified antirheumatic treatment. Assessed at scheduled and unscheduled visits. |
0-24 months
|
|
Number of unscheduled rheumatology visits due to disease worsening
Prazo: 0-24 months
|
Number of unscheduled telephone or in-person rheumatology consultations due to worsening of the participant's inflammatory joint disease |
0-24 months
|
|
Number and type of adverse events
Prazo: 12 and 24 months
|
Number and nature of adverse events and serious adverse events since the previous assessment |
12 and 24 months
|
|
Number of participants with changes in anti-rheumatic medication
Prazo: 12 and 24 months
|
Number of participants with changes in antirheumatic treatment since the previous assessment |
12 and 24 months
|
|
Number and type of medication-related side effects
Prazo: 12 and 24 months
|
Number and type of side effects attributed to medication since the previous assessment |
12 and 24 months
|
|
Proportion of participants using NSAIDs and/or analgesics
Prazo: Baseline, 12, and 24 months
|
Proportion of participants reporting use of NSAIDS and/or analgesics |
Baseline, 12, and 24 months
|
|
Number of antibiotic prescriptions dispensed
Prazo: 12 and 24 months
|
Number of antibiotic prescriptions dispensed to each participant since the previous assessment, obtained from the Norwegian Prescription Database |
12 and 24 months
|
|
Overall satisfaction with care
Prazo: Baseline, 12, and 24 months
|
A single item from the Nordic Patient Experiences Questionnaire (NORPEQ) on overall satisfaction with care, rated on a five-point Likert scale from very satisfied to very dissatisfied, lower score indicates higher satisfaction |
Baseline, 12, and 24 months
|
|
Medication adherence assessed with the MARS-5 questionnaire
Prazo: Baseline, 12, and 24 months
|
Self-reported adherence to anti-rheumatic medication measured with the Medication Adherence Report Scale-5 (MARS-5), consisting of five items each scored 1-5 (total range 5-25). Higher scores indicate greater adherence. Participants with a score ≥23 are classified as adherent. |
Baseline, 12, and 24 months
|
|
Diagnosis-specific composite disease activity score
Prazo: Baseline, 12, and 24 months
|
Disease activity is assessed using a composite score specific to diagnosis (JADAS27 for JIA, DAS28 for RA, ASDAS for SpA and DAPSA for PsA). DAS28 assessed in addition to JADAS27 in participants with JIA. Higher scores indicate more disease activity. |
Baseline, 12, and 24 months
|
|
C-reactive protein (CRP)
Prazo: Baseline, 12, and 24 months
|
CRP (mg/L), with higher values indicating more inflammation |
Baseline, 12, and 24 months
|
|
Erythrocyte sedimentation rate (ESR)
Prazo: Baseline, 12, and 24 months
|
ESR (mm/h), with higher values indicating more inflammation |
Baseline, 12, and 24 months
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Patient-reported pain
Prazo: Baseline, 12, and 24 months
|
General pain last 7 days measured with a single item on a numeric rating scale (NRS) from 0 (no pain) to 10 (worst possible pain) |
Baseline, 12, and 24 months
|
|
Patient-reported fatigue
Prazo: Baseline, 12, and 24 months
|
General fatigue last 7 days measured with a single item on a numeric rating scale (NRS) from 0 (no fatigue) to 10 (worst possible fatigue) |
Baseline, 12, and 24 months
|
|
Patient global assessment of disease activity
Prazo: Baseline, 12, and 24 months
|
The patient global assessment of disease activity (last 7 days) component of the diagnosis-specific composite measure, standardized to NRS 0-10, with higher scores indicating more disease activity |
Baseline, 12, and 24 months
|
|
Health-related quality of life as assessed by the EuroQol 5 Dimension 5 Level questionnaire
Prazo: Baseline, 12, and 24 months
|
Health-related quality of life measured with EuroQol Quality of Life 5 Dimensions 5 Level (EQ-5D-5L), covering mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Summarized as an index value with higher values indicating higher quality of life. |
Baseline, 12, and 24 months
|
|
Self-reported overall health
Prazo: Baseline, 12, and 24 months
|
EuroQol single item. Reported on a visual analog scale 0-100, higher value indicates greater self-assessed overall health status |
Baseline, 12, and 24 months
|
|
Impairment in non-work activities as assessed by the Work Productivity and Activity Impairment Questionnaire (WPAI)
Prazo: Baseline, 12, and 24 months
|
Item 6 of the Work Productivity and Activity Impairment questionnaire (WPAI) , converted to 0-100% impairment in non-work activities. Higher percentage indicates greater impairment. |
Baseline, 12, and 24 months
|
|
Mental well-being as assessed by the WHO-5 Well-Being Index
Prazo: Baseline, 12, and 24 months
|
Self-reported mental well-being measured with the five-item WHO-5 Well-Being Index. Raw score 0-25, with higher scores indicating better wellbeing |
Baseline, 12, and 24 months
|
|
Number of hospital contacts
Prazo: 0-24 months
|
Number of hospital contacts (outpatient visits and admissions), obtained from the Norwegian Patient Register |
0-24 months
|
|
Number of dispensed prescriptions of anti-rheumatic medication
Prazo: 0-24 months
|
Number and type of anti-rheumatic medication prescriptions dispensed, obtained from the Norwegian Prescription Database (NorPD)[N |
0-24 months
|
|
Number of primary care contacts
Prazo: 0-24 months
|
Number of contacts with primary care (e.g. general practitioner and emergency primary care), obtained from the Control and Payment of Health Reimbursements (KUHR) database |
0-24 months
|
|
Costs related to hospital visits
Prazo: Baseline
|
Self-reported travel distance in kilometers to the hospital. |
Baseline
|
|
Costs related to hospital visits
Prazo: Baseline
|
Self-reported way of transport to the hospital; walking or bicycling/private car/public transportation/taxi/airplane/other. |
Baseline
|
|
Proportion of participants in paid work who need to take time off work for rheumatology consultations
Prazo: Baseline
|
Participants in paid work report whether they need to take time off work to attend rheumatology consultations at the hospital, whether in person, by telephone, or by video (yes/no). Participants who are not in paid work are not asked to answer this item. |
Baseline
|
|
Incremental cost-effectiveness ratio
Prazo: 0-24 months
|
Within-trial cost-utility analysis. Quality-adjusted life years (QALYs) estimated from EQ-5D-5L, results presented as incremental cost per QALY gained |
0-24 months
|
|
Patient satisfaction with remote monitoring
Prazo: 12 and 24 months
|
Service User Technology Acceptability Questionnaire (SUTAQ) reported by the Remote monitoring group. 22 items in 5 subscales. Score range 1-6. Higher scores in subscales 1,2 and 5/lower scores in subscales 3 and 4 indicate higher acceptability with telehealth. |
12 and 24 months
|
|
Completion of scheduled triage questionnaire and use of the digital platform
Prazo: 3-21 months
|
Proportion of scheduled triage questionnaires (3, 6, 9, 12, 15, 18 and 21 months) completed, and patterns of interaction with the MyDignio platform. Asessed in the remote follow-up group only |
3-21 months
|
|
Number of withdrawals or early discontinuation
Prazo: 0-24 months
|
Number of withdrawals/early discontinuation |
0-24 months
|
|
Patient-reported self-efficacy for using different digital devices, secure login and digital health services
Prazo: Baseline
|
Self-efficacy/confidence in using smartphone, tablet, computer, app's, secure login and digital health services. 6 items with Likert scale response categories: Never used, Very bad, Bad, Neither good nor bad, Good, Very good. Score range 0-5; higher scores indicate higher self-efficacy. |
Baseline
|
|
eHealth literacy
Prazo: Baseline
|
20 items from 4 domains of the eHealth Literacy Questionnaire (eHLQ). Four-point response scale, sum domain score range 1-4. Lower scores indicate lower eHealth literacy. |
Baseline
|
|
Travel-related carbon footprint of in-person consultations
Prazo: 0-24 months
|
Estimated greenhouse gas emissions (kg CO2-equivalents per participant) from travel to and from in-person rheumatology consultations. Calculated from the number of in-person consultations, self-reported travel distance and usual mode of transport, and emission factors per passenger-kilometre. |
0-24 months
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças ósseas
- Doenças musculoesqueléticas
- Artrite
- Doenças articulares
- Doenças Reumáticas
- Doenças do Tecido Conjuntivo
- Doenças autoimunes
- Doenças do sistema imunológico
- Doenças da coluna vertebral
- Espondilartropatias
- Doenças de Pele Papuloescamosas
- Doenças de pele
- Espondilite
- Psoríase
- Doenças da Pele e do Tecido Conjuntivo
- Artrite Juvenil
- Espondilartrite
- Artrite, Reumatóide
- Artrite, Psoriática
Outros números de identificação do estudo
- DS-26/00970
- 2025064 (Número de outro subsídio/financiamento: South-Eastern Norway Regional Health Authority)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .